BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12396813)

  • 1. Cost effectiveness: summary.
    Ringel SP
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002; 3 Suppl 1():S67-9. PubMed ID: 12396813
    [No Abstract]   [Full Text] [Related]  

  • 2. Slowing down ALS--is this good or bad?
    Munsat TL
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2001 Mar; 2 Suppl 1():S19-22. PubMed ID: 11465919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness associated with amyotrophic lateral sclerosis: some questions and answers pending.
    Fiorentino G; Esquinas AM
    Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):315-316. PubMed ID: 29191046
    [No Abstract]   [Full Text] [Related]  

  • 4. A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole.
    Thakore NJ; Pioro EP; Udeh BL; Lapin BR; Katzan IL
    Value Health; 2020 Dec; 23(12):1543-1551. PubMed ID: 33248509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK.
    Tavakoli M; Malek M
    J Neurol Sci; 2001 Oct; 191(1-2):95-102. PubMed ID: 11676998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness: con.
    Ramsey S
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002; 3 Suppl 1():S65-6. PubMed ID: 12396812
    [No Abstract]   [Full Text] [Related]  

  • 8. Riluzole.
    Gelinas DF
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2000 Dec; 1 Suppl 4():3-4. PubMed ID: 11466957
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost effectiveness: pro the value of economic information in medical decision-making.
    Woolley JM
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002; 3 Suppl 1():S63-4. PubMed ID: 12396811
    [No Abstract]   [Full Text] [Related]  

  • 10. Factors influencing a patient's decision regarding riluzole: an early experience.
    Rudnicki SA
    J Neurol Sci; 1997 Oct; 152 Suppl 1():S80-1. PubMed ID: 9419060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Any placebo controlled trial of riluzole would surely be unethical now.
    Ford M; Leperlier C
    BMJ; 2001 Sep; 323(7312):573-4. PubMed ID: 11573491
    [No Abstract]   [Full Text] [Related]  

  • 12. [Riluzole treatment in amyotrophic lateral sclerosis].
    Wokke JH
    Ned Tijdschr Geneeskd; 1996 Nov; 140(46):2265-8. PubMed ID: 8984377
    [No Abstract]   [Full Text] [Related]  

  • 13. Rilutek (Riluzole) may extend survival in amyotrophic lateral sclerosis.
    J Neurosci Nurs; 1996 Aug; 28(4):275. PubMed ID: 8880606
    [No Abstract]   [Full Text] [Related]  

  • 14. A fair innings for NICE?
    Freemantle N; Bloor K; Eastaugh J
    Pharmacoeconomics; 2002; 20(6):389-91. PubMed ID: 12052097
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis.
    Ginsberg GM; Lev B
    Pharmacoeconomics; 1997 Nov; 12(5):578-84. PubMed ID: 10174324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Amyotrophic lateral sclerosis. Fatal diagnosis -- how still can be helped?].
    Stiefelhagen P
    MMW Fortschr Med; 2004 Nov; 146(47):16. PubMed ID: 15624649
    [No Abstract]   [Full Text] [Related]  

  • 17. [Etiological drug therapy for amyotrophic lateral sclerosis].
    Cintas P
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S220-4S227. PubMed ID: 17128115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preface: the state of the science of all motor neuron diseases.
    Weiss MD; Carter GT
    Phys Med Rehabil Clin N Am; 2008 Aug; 19(3):xix-xx. PubMed ID: 18625405
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmacotherapy of amyotrophic lateral sclerosis].
    Jokelainen M
    Duodecim; 1997; 113(6):513-6. PubMed ID: 11370073
    [No Abstract]   [Full Text] [Related]  

  • 20. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment.
    Andreadou E; Kapaki E; Kokotis P; Paraskevas GP; Katsaros N; Libitaki G; Zis V; Sfagos C; Vassilopoulos D
    Clin Neurol Neurosurg; 2008 Mar; 110(3):222-6. PubMed ID: 18055102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.